Singapore: Cancer Council NSW, Australia's non-government cancer research funder, has granted almost $7 million to resea...
Singapore: US-Australian drug discovery company, Novogen, in conjunction with Australian paediatric cancer researchers, ...
Singapore:Â The World Health Organization (WHO) is urging governments to act against the five hepatitis viruses that can...
Singapore: Australian drug discovery company, Novogen, has developed anti-tropomyosin drug candidate, Anisina, which has...
Singapore: Australia-based Starpharma Holdings has achieved improved tumor-inhibiting efficacy and reduced overall toxic...
Singapore:Â Australian drug delivery technology company, Phosphagenics, will be returning to the clinic with its oxycodo...
The drug delivery technology landscape is rapidly evolving with new classes of pharmaceuticals and biologics fuelling th...
Singapore: Australia based pharmacuetical company, Starpharma, has appointed Mr Robert Thomas to the Board as a non-exec...
Singapore: Australia's Balnaves Foundation has donated $450,000 to the University of Sydney's medical school to help pro...
Singapore: Australian biopharmaceutical company, Specialised Therapeutics Australia (STA), and Helsinn, a Swiss group fo...
Singapore: Two approved drugs, an antifungal and a steroid, may potentially take on new roles as treatments for multiple...
Singapore: A group of researchers from Institute of Bioengineering and Nanotechnology (IBN) is using green tea ingredien...
Singapore: Singapore and Scotland based TauRx Pharmaceuticals, a clinical-stage biopharmaceutical company developing a n...
Singapore: Phase II clinical trials by scientists from the National Institute of Allergy and Infectious Diseases (NIAID)...
Singapore: Daiichi Sankyo is going to establish a new company named Orphan Disease Treatment Institute, along with Innov...
Singapore: Sinovac Biotech, a leading China-based vaccine manufacturer, has been selected by the Jiangsu Centers for Dis...
Sydney-headquartered Regeneus announced the completion of enrolment of all 20 patients in the STEP trial. Further, a rev...
Singapore: Pfizer's high hopes for its JAK3 (Janus kinase) inhibitor, tofacitinib (tasocitinib, CP-690550), now branded ...
